Gaithersburg’s Sirnaomics Secures $105 Million in Series E Financing to Fund Development of Novel RNAi Therapeutics

Published on :

Proceeds to Fund Development of Novel RNAi Therapeutics for Cancers, Viral Infections, Fibrosis, and Metabolic Diseases

Intralytix Receives SBIR Grant to Develop Phage Preparation for Reducing Vibrio parahaemolyticus Contamination of Foods

Published on :

Intralytix, Inc. announced today that it has received a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Food and Agriculture (NIFA), an agency of the U.S. Department of Agriculture (USDA), for the development of a phage biocontrol solution for Vibrio parahaemolyticus
in various food products.

Commission Appoints Amritha Jaishankar, Ph.D. as Executive Director, Maryland Stem Cell Research Fund (MSCRF)

Published on :

The Maryland Stem Cell Research Commission (Commission) announces the appointment of Amritha Jaishankar, PhD as Executive Director, Maryland Stem Cell Research Fund (MSCRF).

BHCR passes San Francisco in NIH funding

Johns Hopkins University Peabody Research Library
Published on :

The National Institutes of Health provides significant funding for drug development research to universities, companies, and organizations. Over the course of 2020, the NIH provided a significant amount of funding to the BioHealth Capital Region.

End of Year Update: 2020 Life Science Venture Capital Funding Roundup in the BioHealth Capital Region

Published on :

This has certainly been a year unlike any other for BioHealth Capital Region (BHCR) life science companies of all sizes and kinds. Just a few months into 2020, the coronavirus pandemic swept the region, seriously disrupting, albeit temporarily, the best laid plans of aspiring founders, entrepreneurs, emerging startups, pre-clinical and more established, larger biohealth organizations in Virginia, Washington, D.C. and Maryland.

Seeking Funding During a Pandemic: Panel Discusses Recent Trends in Life Science Capital

Published on :

COVID-19 has created significant challenges for the Venture Capital (VC) market and life science companies seeking funding during the pandemic. While the pandemic has undoubtedly added a new layer of risk to an inherently risky field, the fundamentals for what makes a company attractive to a VC have remained steady.

5 Questions with Tammi Thomas, Vice President, Marketing & Communications at TEDCO

Published on :

Andrew Davis is Vice President at Scheer Partners and helps run the scientific real estate practice. Andrew lives in Maryland but assists scientific companies identify, negotiate, and build space in the Biohealth Capital Region, Philadelphia / Greater PA, and Massachusetts.